interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Lenvatinib Mesylate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Lenvatinib Mesylate, and who makes it?

Lenvatinib Mesylate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Lenvatinib Mesylate1 dosage-form group in the Orange Book
0generic makers listed
  1. Lenvatinib Mesylate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Lenvima. No generic is listed as marketed.

20152020202520302035204001brand 2015data datePatent 7612208*PED listed to expire 19 March 2027Patent 9006256 listed to expire 27 July 2027Patent 9006256*PED listed to expire 27 January 2028Patent 12508313 listed to expire 4 October 2030Patent 12508313*PED listed to expire 4 April 2031Patent 11186547 listed to expire 26 August 2035Patent 10407393 listed to expire 26 August 2035Patent 10259791 listed to expire 26 August 2035Patent 11090386 listed to expire 23 February 2036Patent 11186547*PED listed to expire 26 February 2036Patent 10407393*PED listed to expire 26 February 2036Patent 10259791*PED listed to expire 26 February 2036Patent 12083112 listed to expire 3 March 2036Patent 11090386*PED listed to expire 23 August 2036Patent 12083112*PED listed to expire 3 September 2036Patent 12226409 listed to expire 15 May 2038Patent 12226409*PED listed to expire 15 November 2038Exclusivity M-14 to 3 April 2027Exclusivity PED to 3 October 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 3 April 2027Exclusivity M-14 Lenvima
  • 3 October 2027Exclusivity PED Lenvima
  • 19 March 2027Patent 7612208*PED
  • 27 July 2027Patent 9006256
  • 27 January 2028Patent 9006256*PED
  • 4 October 2030Patent 12508313 drug product
  • 4 April 2031Patent 12508313*PED
  • 26 August 2035Patent 11186547 drug substance
  • 26 August 2035Patent 10407393 drug substance
  • 26 August 2035Patent 10259791 drug substance

9 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.